Harvard Pilgrim Health Care Home
  Learn more.
  Sign up for HPHConnect.
Medical Management
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Office Support
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

December 2017

New Policy: Maximum Dosages for Medical Drugs

Earlier this year, Harvard Pilgrim expanded our prior authorization program for select medical drugs and is continuing efforts to ensure the safe, cost-effective, and appropriate use of medications through a new maximum allowed dosage policy.
Effective for dates of service beginning Feb. 26, 2018, Harvard Pilgrim will apply industry standard claims edits and will not reimburse for drug dosages above limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines for the medical drugs listed here for our commercial members.
Under our new Drug Dosage and Frequency Medical Policy, the drug dosage, frequency and route of administration should be supported by one or more of the following for the treatment indication: 

  • U.S. Food and Drug Administration prescribing information
  • National Comprehensive Cancer Network Drug & Biologics Compendium
  • American Hospital Formulary Service Drug Information
  • DRUGDEX System

Harvard Pilgrim reserves the right to conduct post-payment review and audit of claims submitted for drugs and may recover payments made for amounts in excess of the FDA labelling.

For more information, please refer to the Drug Dosage and Frequency Medical Policy and the Medical Drug Management Prior Authorization Policy. Also, look for additional information in upcoming issues of Network Matters.

Email this article to a colleague   

Network Matters Archives

Download printer-friendly version


New Monthly Publication Date for Network Matters

New Policy: Maximum Dosages for Medical Drugs

Webinar for Genetic Testing Authorization for Medicare Members

New Medicare Beneficiary Identifier Coming in 2018

Methadone Maintenance Benefit Change in Massachusetts

Study Suggests Breastfed Babies Are Less Likely to Have Eczema as Teens


Changes to Premium Formulary for 2018

New Prior Authorization Policy for Radicava

Keytruda and Opdivo Prior Authorization Policies Updated

Depression Screening and Treatment


Keep Panel Status and Demographic Information Up to Date


Eric H. Schultz,
President and Chief Executive Officer

Robert Farias,
Senior Vice President, Network Strategy

Annmarie Dadoly,

Joseph O'Riordan,

Kristin Edmonston,
Production Coordinator